Bone marrow side population (SP) cells were initially discovered as a small population of early haematopoietic stem cells defined by their unique exclusion capacity for the vital day Hoechst 33342.
1 SP cells are CD34-negative and exert predominantly long-term repopulation capacity after transplantation in mice. SP cells have also been isolated from bone marrow of other mammalian species, and in primates these cells were shown to generate CD34-positive haematopoietic stem cells. 2 Bone marrow SP cells from patients with acute myeloid leukaemia (AML) harbour progenitor cells of the malignant clone, capable of establishing leukaemia in xenotransplantation systems, and recently cells of this phenotype have also been described as tumour progenitor cells in solid neoplasm. [3] [4] [5] The extrusion capacity of SP cells for xenobiotic substances also extends to cytostatic drugs such as daunorubicin, endowing these cells with an intrinsic mechanism of chemotherapy resistance. 3, 4 After myeloablative total body irradiation (TBI) followed by syngeneic transplantation in mice, we previously documented a prolonged persistence of mixed chimerism on the level of bone marrow SP cells, contrasting to full-donor chimerism in whole marrow and peripheral blood cell preparations. 6 This finding raised our interest for the situation in humans, regarding both their role for the understanding of haematopoietic engraftment, and the control of residual malignant cells after stem cell transplantation.
We here dissected the chimerism within the compartments of SP vs non-SP cells from bone marrow aspirates from patients after allogeneic stem cell transplantation. Specimens were obtained from material sampled for diagnostic purposes. Bone marrow SP cells vs non-SP cells were identified and isolated as described before. 1 Briefly, the mononuclear cell fraction after Ficoll density centrifugation was stained with Hoechst 33342 for 90 min at 371C. Hoechst 33342 effluxing cells were identified by their characteristic fluorescence profile in dual colour analysis ( Figure 1 ), and isolated by flow cytometric sorting on a FACS Vantage SE (Becton-Dickinson). Following DNA extraction from the sorted cell fractions or from whole bone marrow smears, chimerism was determined by donor and recipient specific short tandem repeat analysis of nine genomic loci, as described. 7 Briefly, DNA fragments were amplified by polymerase chain reaction using fluorescent dye-labelled oligonucleotides according to the manufacturer (AmplFlSTR Profiler, Perkin-Elmer), and the products analysed on a genescan analyser (ABI PRISM 310 Genetic Analyser). The mean value of at least three informative loci, expressed in percent of donor vs recipient specific product, was taken as degree of chimerism.
Results for bone marrow cell populations were obtained from 11 patients after HLA-identical allogeneic stem cell transplantation to treat haematological malignancies (Table 1) . Eight and three patients had received reduced intensity (RIC) or full myeloablative conditioning, respectively, and grafts yielded from mobilised peripheral stem cells in 10 as well as from unmanipulated bone marrow in one case. SP cells were detected in all specimens analysed, at a mean percentage of 0.84 (range 0.01-0.49%). At a median interval of 10 months (range 1-26 months) after transplantation, the mean donor chimerism was 96% in SP (range 72-100%, n ¼ 9), compared to 100% in the non-SP cells (n ¼ 8), and 93% (range 83-100%, n ¼ 5) from whole marrow smear DNA extracts ( Table 1 ). The only patient with a significant mixed chimerism (case 5) was the patient analysed at the shortest interval post transplantation (1 month). No differences were observed between samples of patients after reduced intensity vs myeloablative conditioning.
Thus, in humans after allogeneic transplantation, mixed chimerism on the level of bone marrow SP cells is an exceptional, rather than a regular finding as in mice after syngeneic transplantation. It remains open, whether this is due to differences in the biology of SP cells from mouse and man, or whether any recipient SP cells surviving the conditioning therapy are eliminated by graft-versus-host activity of the incoming immune system. Favouring the latter and given that SP cells harbour the malignant clone in most patients with AML, graft-versus-host effects would be effective against both normal and leukaemia recipient SP Reduced intensity conditioning (RIC) regimens were fludarabine/busulfan/cyclophosphamide (FBC-12), 9 or fludarabine/cyclophosphamide (FC), and allogeneic peripheral blood or bone marrow stem cells (PBSC and BMSC, respectively) were obtained from HLA-identical siblings (sib) or matched unrelated donors (MUD). The proportion of SP cells in the bone marrow specimens is listed in percent (SP (%) wbm).
